Deepika Vuppalanchi, PhD, is co-founder, CEO, and chair of Syra Health. Prior to starting Syra Health, Deepika obtained her doctoral degree in molecular biology and genetics from the University of Delaware. She continued to work as a research scientist for renowned institutions before moving to the private sector.
Working in the healthcare industry, Deepika gained experience in many areas including healthcare strategy, education and outreach. She worked in leadership roles for global pharmaceutical companies, government agencies, and managed care entities.
Deepika co-founded Syra Health after realizing a lot of healthcare services are a one-size fits all model, when in reality healthcare solutions need to be integrated, customized, and cost-effective.
Priya Prasad is Chief Financial Officer and Chief Operating Officer for Syra Health. Priya is an experienced and proven leader, having served as president of STLogics, a holding company, for more than 17 years. She received her MBA from the University of Massachusetts Boston, as well as a Master's degree in Environmental Science.
Ms. Rogers has over 19 years of senior leadership experience. Since March 2022, Ms. Rogers has served as the Chief Financial Officer of Johns Hopkins All Children’s Hospital. Previously, from August 2020 to March 2022, Ms. Rogers served as the Chief Financial Officer and Chief Strategy Officer of Eskenazi Health, a public hospital that offers a comprehensive range of inpatient, primary and specialty care services.
Since November 2018, Dr. Dahlem has served as Senior Research Professor of Medicine at the Indiana University School of Medicine and also served as Chief of the Division of Clinical Pharmacology until May 2022. Dr. Dahlem is co-founder and has served as an advisor to Gate Neurosciences, a biotechnology company focused on new therapies for treatment resistant depression, since April 2019 and President of Dr. Dahlem Consulting LLC, advising on the discovery and development of novel therapeutics for academia, biotech and the pharmaceutical industry since May 2018. Furthermore, Dr. Dahlem also served as Vice President of Research Operations and Chief Operating Officer of Lilly Research Laboratories and Lilly Research Laboratories Europe at Eli Lilly and Company until his retirement in December 2017.
Dr. Reddy is a drug development professional with over 30 years of experience in drug discovery and development in global pharmaceutical industry. Since August 2017, Dr. Reddy has served as an advisor as well as a Director of VIPRA, LLC, a consulting company. Dr. Reddy currently serves as a consultant for various pharmaceutical, biotechnology and vaccine companies. From 2007 to 2017, Dr. Reddy served as a Senior Researcher Advisor/Executive Director at Lilly Research Laboratories, at Lilly, where he led nonclinical safety and regulatory assessments on several cross functional programs at different stages of development.
Dr. Paranjape is an accomplished commercial and technology leader, with 25 years of demonstrated experience at developing and commercializing digital solutions across healthcare, pharmaceutical, automotive, telecommunication, gaming, and animation. His roles have included chief operating officer of enterprise imaging at Optum, head of commercial business operations and transformation at Roche, along with leading the commercialization of the Navify digital platform. He was a managing director at Health2047, for-profit incubator funded by the American Medical Association and prior to that ran the life sciences business at Intel along with being the global head of product and engineering for multiple solutions for customers such as BMW, Boeing, Pixar, AT&T, Novartis and GE. He has a Ph.D. in applying artificial intelligence to Healthcare, MBA in Finance, and along with being on the roster of experts on Digital Health at the World Health Organization, he has participated on the US Health IT Standards Committee Precision Medicine Task Force, AAAS-FBI-UNICRI Project on Life Sciences and National and Transnational Security, International Telecommunication Union’s Global Cybersecurity Working Group and WHO’s Experts Working Group on eHealth.
Dr. Reddy has over 25 years of leadership experience in both in research and development and business. Dr. Reddy has been serving as the Scientific Strategic Intelligence Leader since 2017 at Corteva Agriscience (NYSE: CTVA), an agricultural chemical and seed company and spin-off from Dow-DuPont. Dr. Reddy joined Dow AgroSciences in January 1999 and served in various roles including R&D Innovation Incubator Leader from January 2015 to December 2017, Competitive Intelligence Leader from January 2009 to December 2017, Global Traits Discovery Platform Leader from January 2005 to December 2008, Global Leader of Molecular Biology and Traits from January 2002 to December 2004, and Global Leader of Genomics from January 1999 to December 2001.